This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E75.5 | Special Copayment Reduction: V117 (5 years) |
| B. Synonyms | Van Bogaert-Scherer-Epstein disease, cholestanolosis, cerebrotendinous xanthomatosis, familial sterol storage disease |
| C. Adult onset | Likelihood of first onset in adulthood: moderate — begins with jaundice in the neonatal period to childhood, but neurological symptoms appear in adolescence to adulthood; diagnosis is often delayed until adulthood |
| 1. History | History from the first description by Van Bogaert et al. in 1937 and Setoguchi's discovery of cholestanol in 1968 to the identification of the CYP27A1 gene |
| 2. Causes | CYP27A1 mutations cause sterol 27-hydroxylase deficiency → tissue accumulation of cholestanol and cholesterol |
| 3. Genetics | Autosomal recessive inheritance; CYP27A1 gene (2q35); more than 70 pathogenic variants; founder effect in Moroccan Jews of North African origin |
| 4. Epidemiology | Estimated at 1 per 50,000–100,000 births worldwide; higher prevalence in certain populations; average diagnostic delay 15–20 years |
| 5. Pathophysiology | Blocked bile acid synthesis → cholestanol overproduction → accumulation in tendons, brain, lens, and blood vessels → xanthomas and neuroinflammation |
| 6. Symptoms | Tendon xanthomas (Achilles and hand tendons), early cataracts, diarrhea (infancy), progressive neurological symptoms (cerebellar ataxia, dementia, seizures, extrapyramidal) |
| 7. Signs | Tendon xanthomas, cataracts, abnormal signal of the cerebellar dentate nucleus on MRI, elevated plasma cholestanol, abnormal urinary bile acids |
| 8. Screening | Plasma cholestanol measurement (GC-MS), urinary bile acid analysis, neonatal DBS biomarker (7α12αC4) at research stage |
| 9. Diagnosis | Plasma cholestanol measurement by GC-MS, CYP27A1 gene analysis, brain MRI, urinary bile acid profile analysis |
| 10. Treatment | Long-term chenodeoxycholic acid (CDCA, 750 mg/d); add statin; adjunctive agents; early treatment may delay neurological progression |
| 11. Prognosis | Irreversible neurological damage if diagnosis is delayed; early CDCA treatment can halt progression and allow partial recovery; without treatment, severe disability by the 40s–50s |
| 12. Prevention | Genetic counseling, carrier testing, newborn screening (in development); early recognition and diagnosis are key |
| 13. References | Berginer VM et al. (1984) N Engl J Med and 9 other papers |
The first clinical description of cerebrotendinous xanthomatosis (CTX) comes from a 1937 paper jointly published by Belgian neurologist Ludo Van Bogaert, German internist Scherer, and Epstein of the United States. They described three patients characterized by progressive neurological symptoms, tendon xanthomas, and cataracts, and the disease was named 'Van Bogaert-Scherer-Epstein disease' after the three authors.
Initially the etiology was unclear, but elucidation of the molecular pathogenesis began in the 1960s. In 1968, Setoguchi and Mosbach found that cholestanol, which resembles cholesterol but has a 5α-saturated structure, was abnormally accumulated in the tissues of CTX patients. In 1974, Salen and Shefer demonstrated that deficiency of the bile acid synthesis enzyme sterol 27-hydroxylase is the core pathogenesis of CTX, establishing the link between abnormal cholestanol metabolism and blocked bile acid synthesis.
In 1983, Berginer et al. first reported that oral chenodeoxycholic acid (CDCA) lowers blood cholestanol levels and improves clinical symptoms in CTX, marking a breakthrough in CTX treatment. In 1991, Cali et al. identified the CYP27A1 gene encoding sterol 27-hydroxylase at 2q35, after which molecular diagnosis became possible. In Korea, it is registered under Special Copayment Reduction code V117 (ICD-10: E75.5).
CTX is caused by deficiency of mitochondrial sterol 27-hydroxylase due to pathogenic variants of the CYP27A1 gene. Sterol 27-hydroxylase is a key enzyme in the bile acid synthesis pathway that catalyzes hydroxylation of the cholesterol side chain, and is essential for the conversion of cholesterol to chenodeoxycholic acid (CDCA) and cholic acid in the liver.
When the CYP27A1 enzyme is deficient, bile acid synthesis is blocked and intermediate metabolites of the bile acid synthesis pathway are diverted to alternative pathways, producing abnormally large amounts of cholestanol (5α-cholestan-3β-ol). Cholestanol is structurally similar to cholesterol but is a saturated form in which the double bond between carbons 5 and 6 is reduced; it accumulates in tissues such as the brain, tendons, lens, and vessel walls, causing xanthoma formation and nerve damage. In addition, CYP27A1 deficiency reduces negative feedback by bile acids in the liver, causing upregulation of cholesterol 7α-hydroxylase (CYP7A1), which sets up a vicious cycle that further increases production of precursor metabolites.
Plasma cholestanol levels in CTX patients are elevated 5–10 times above normal controls, while total cholesterol may be normal or low. This is one of the reasons CTX is difficult to suspect clinically.
CTX follows an autosomal recessive mode of inheritance. The CYP27A1 gene is located on the long arm of chromosome 2 at band 35 (2q35) and consists of 9 exons. Sterol 27-hydroxylase is a member of the cytochrome P450 enzyme family located in the inner mitochondrial membrane and consists of 531 amino acids.
More than 70 pathogenic CYP27A1 variants have been reported to date, of various types including missense, nonsense, splice site, deletion, and insertion. In most cases the variants are specific to individual families, but founder mutations have been identified in some populations. In Moroccan Sephardic Jews, the c.379C>T (p.Arg127Trp) variant is known as a founder mutation, and CTX prevalence in this population is dozens of times higher than in the general population. In Japanese patients, the c.1183C>T (p.Arg395Cys) variant is reported relatively often.
Genotype–phenotype correlation has been established only to a limited extent in CTX. Some studies have reported associations between specific variants and disease severity or age of onset, but the phenotype can vary even within the same family. Carriers are asymptomatic, and the carrier frequency in the general population is estimated at about 1/150–1/300. Molecular diagnosis by gene panel or whole-exome sequencing (WES) is recommended.
CTX is a rare disease with an estimated worldwide incidence of 1 per 50,000–100,000 births, but because diagnosis tends to be greatly delayed, the actual prevalence is likely higher. According to the literature, the average delay to diagnosis reaches 15–20 years, owing to the diversity of symptoms and low clinical awareness.
Higher prevalence is reported in certain ethnic groups. In Moroccan Sephardic Jews (living in Israel), a high prevalence of about 1/400 is estimated, attributable to a founder effect. Relatively many cases have also been reported in Japan, Italy, and Middle Eastern countries. There is no difference in occurrence by sex. In Korea, cases are rarely reported, and accurate domestic prevalence statistics have not yet been established.
Although CTX is a treatable rare genetic disease, early diagnosis is very difficult, so it is important that clinicians who encounter its characteristic clinical signs (tendon xanthomas + early cataracts + neurological symptoms) actively suspect CTX. Biomarker research aimed at introducing newborn screening has recently been active.
The pathophysiology of CTX is understood as centering on impaired bile acid synthesis due to CYP27A1 enzyme deficiency, and the resulting overproduction and tissue accumulation of cholestanol.
In the normal bile acid synthesis pathway, sterol 27-hydroxylase catalyzes hydroxylation at position 27 of the cholesterol side chain, ultimately leading to production of CDCA and cholic acid. In CYP27A1 deficiency this pathway is blocked, and bile acid precursors (especially 5β-cholestane-3α,7α,12α-triol, etc.) accumulate. These precursors are abnormally converted to cholestanol via alternative pathways. In addition, upregulation of CYP7A1 expression due to decreased blood CDCA further worsens the overproduction of bile acid synthesis precursors.
Cholestanol accumulates in the cerebral white matter, the cerebellar dentate nucleus, tendons (especially the Achilles tendon), the lens, atherosclerotic lesions, the lungs, and elsewhere, causing xanthoma formation. In the brain, accumulation of cholestanol and cholesterol causes myelin dysfunction, neuroinflammation (microglial activation, cytokine secretion), and axonal damage, leading to progressive neurodegeneration. T2 hyperintensity of the cerebellar dentate nucleus and cerebellar atrophy on MRI reflect this pathology. Early atherosclerosis and osteoporosis are also systemic complications related to cholestanol accumulation.
CTX is a multisystem disease with different clinical manifestations appearing at various ages. Symptoms appear in stages from the neonatal period to adulthood, and neurological symptoms usually become prominent after adolescence.
Jaundice due to reduced bile secretion (neonatal cholestasis) may appear in the neonatal period; it often resolves spontaneously in infancy, so the diagnosis is easily missed. Chronic diarrhea appears from infancy, reflecting fat malabsorption due to bile acid deficiency.
Premature cataracts are one of the most characteristic early signs appearing in childhood. They are often bilateral, and CTX is frequently overlooked as a cause of pediatric cataracts in general. Delayed intellectual development or learning disabilities may be recognized during this period.
Tendon xanthomas appear in the Achilles tendon, triceps tendon, finger extensor tendons, and elsewhere. At the same time, progressive neurological symptoms begin. Cerebellar ataxia, dysarthria, dysphagia, pyramidal signs (spasticity, limb paresis), peripheral neuropathy, and seizures appear, and cognitive decline and neuropsychiatric symptoms (depression, mania, psychosis) may accompany them.
Neurological symptoms continue to progress, and dementia, parkinsonism, spinal spastic paralysis, and dystonia may appear. The risk of cardiovascular disease due to early atherosclerosis and of fractures due to osteoporosis increases.
Clinical signs and test findings useful in diagnosing CTX are as follows.
Achilles tendon xanthoma is the most characteristic clinical sign, with marked enlargement of the Achilles tendon and nodular xanthoma deposits. Xanthomas may also appear in the triceps tendon, patellar tendon, and finger extensor tendons. Slit-lamp examination shows posterior subcapsular cataracts, characteristically of early onset.
Bilateral T2/FLAIR hyperintensity of the cerebellar dentate nucleus is the most characteristic MRI finding in CTX and has high diagnostic value. T2 hyperintensity and atrophy of the cerebellar hemispheric white matter, cerebellar peduncles, and cerebral hemispheric white matter may also be seen. MR spectroscopy (MRS) shows reduced N-acetylaspartate (NAA) and increased lipid peaks.
Plasma cholestanol measured by GC-MS is elevated 5–10 or more times above normal controls (normal: 2–5 μmol/L; CTX: 10–50 μmol/L), and this is the key diagnostic test. Total cholesterol and LDL are often normal or low, and the absence of hypercholesterolemia is a reason for low clinical suspicion. Plasma bile acids (especially CDCA) are markedly reduced.
Urinary or serum bile acid analysis shows increased abnormal metabolites such as abnormal 7α,12α-dihydroxylated cholestanol derivatives and 5β-cholestane-3α,7α,12α,25-tetrol glucuronide (GlcA-tetrol), which are highly sensitive diagnostic biomarkers of CTX.
CTX is a treatable rare disease, and early diagnosis and initiation of treatment have a decisive effect on prognosis. Various screening strategies are therefore being developed or studied.
GC-MS measurement of plasma cholestanol is currently the most widely used screening and diagnostic test for CTX. It has the limitations of high cost and difficulty in performing it in general clinical laboratories, but it is used as a screening test at rare metabolic disease centers in Europe and the United States. Many institutions use plasma cholestanol > 5.1 mg/dL (14 μmol/L) as the threshold for suspicion.
Recently, 7α,12α-dihydroxy-4-cholesten-3-one (7α12αC4) and GlcA-tetrol have drawn attention as CTX screening biomarkers using newborn DBS. In a retrospective analysis using DBS from 32,000 newborns in a study conducted in the Netherlands, high sensitivity and specificity of 7α12αC4 were reported. Prospective studies are underway toward introducing population-based newborn screening programs.
CTX screening should be actively considered when a combination of the following signs is observed in a child or adolescent: (1) unexplained early cataracts, (2) tendon xanthomas (especially Achilles), (3) neurological symptoms (cerebellar ataxia, cognitive decline), (4) chronic diarrhea in childhood. If two or more of these are present, plasma cholestanol measurement and CYP27A1 genetic testing are performed immediately.
Confirmation of CTX is made by integrating plasma cholestanol measurement, urinary/serum bile acid analysis, CYP27A1 gene analysis, and brain MRI findings.
Gas chromatography–mass spectrometry (GC-MS) measurement of plasma cholestanol is the most important biochemical diagnostic test. In CTX patients, plasma cholestanol is markedly elevated (5–10 times normal), and it is used to establish the diagnosis and to monitor treatment response. However, false negatives are possible in early neonatal life, when cholestanol has not yet sufficiently accumulated.
On bile acid profile analysis using GC-MS or LC-MS/MS, increased GlcA-tetrol, tauro-trihydroxycholestanoic acid (t-THCA), and abnormal C27 bile alcohol glucuronides are characteristic findings of CTX. CDCA and cholic acid are markedly reduced.
Pathogenic variants of the CYP27A1 gene are identified by NGS-based gene panel or Sanger direct sequencing. Confirmation is possible when pathogenic variants are identified on both alleles. Genetic testing is also used for carrier identification and prenatal diagnosis.
Bilateral T2 hyperintensity of the cerebellar dentate nucleus and cerebellar atrophy are characteristic neuroimaging findings of CTX. Cerebral white matter changes and T2 hyperintensity of the posterior columns of the spinal cord may also be observed. CTX must be included in the differential diagnosis in adults showing abnormal signal in the cerebellar dentate nucleus.
Peripheral neuropathy is evaluated by electromyography (EMG/NCS), cataracts by fundus and slit-lamp examination, and bone density by DEXA. Neurocognitive testing quantifies the degree of cognitive decline.
CTX is a treatable rare metabolic disease, and the earlier treatment is started, the more the prognosis improves. The current standard treatment is long-term oral chenodeoxycholic acid (CDCA).
CDCA is given orally at 750 mg per day (adult, based on 50 kg body weight) in 3 divided doses. Exogenous CDCA restores negative feedback on CYP7A1 expression, suppressing production of cholestanol precursors and normalizing plasma cholestanol levels. In clinical studies, long-term CDCA reduced plasma cholestanol, stabilized or partially improved neurological symptoms, reduced tendon xanthoma size, and improved bone density. In particular, the earlier in the course of symptom onset treatment is started, the more effectively neurological progression can be delayed. Adverse effects such as diarrhea and hepatotoxicity (elevated AST/ALT) have been reported, but tolerability is mostly good. When CDCA is given to infants, the risk of hepatotoxicity may increase, so monitoring is needed.
HMG-CoA reductase inhibitors (statins) can provide an adjunctive effect to CDCA therapy by suppressing endogenous cholesterol synthesis and thereby reducing the supply of cholestanol precursors. Adding a statin is considered particularly when LDL cholesterol is elevated.
Seizures are controlled with antiepileptic drugs (valproic acid, levetiracetam, etc.), and physical therapy and walking aids help with cerebellar ataxia. For osteoporosis, bisphosphonates and calcium and vitamin D supplementation are recommended. Cataracts are corrected surgically. Management of cardiovascular risk factors is needed to prevent atherosclerosis.
The prognosis of CTX depends greatly on the timing of diagnosis and the start of treatment. Without treatment, neurological symptoms progress slowly over decades, leading to severe disability (bedridden state, end-stage dementia) by the 40s–50s. Given that the average delay to diagnosis reaches 15–20 years, many patients begin treatment after irreversible nerve damage has already occurred.
The earlier CDCA treatment is started (especially before or early after the onset of neurological symptoms), the more the prognosis improves. When treatment is started before the onset of neurological symptoms, normal or near-normal function can be maintained. When CDCA treatment is started after neurological damage is already present, further progression is suppressed, but complete recovery of existing damage is rare. Normalization of plasma cholestanol levels correlates with clinical stabilization. Tendon xanthomas decrease slowly over months to years after CDCA treatment.
Patients surviving for decades with a normal quality of life through early diagnosis and treatment have been reported. Introduction of newborn screening programs could improve the prognosis of CTX even more dramatically.
CTX is a hereditary disease with no primary prevention, but neurological damage from the disease can be minimized through genetic approaches and building an early diagnosis system.
Genetic counseling must be offered after a CTX patient is identified. Under autosomal recessive inheritance, the parents are carriers, and there is a 25% chance of an affected child in each subsequent pregnancy. Plasma cholestanol measurement and CYP27A1 genetic testing are performed in the patient's siblings to achieve diagnosis before symptom onset.
Carrier status of the patient's family members is determined by CYP27A1 gene analysis. In high-risk ethnic groups (Moroccan Sephardic Jews, etc.), carrier screening before marriage or before planning a pregnancy is considered.
When the pathogenic variants of both parents have been identified, prenatal diagnosis is possible in subsequent pregnancies by CYP27A1 gene analysis via CVS or amniocentesis. Unaffected embryos can be selected for transfer through PGT-M.
Research on newborn DBS-based biomarker (7α12αC4, GlcA-tetrol) screening is underway, and if included in newborn screening programs in the future, it is expected to allow prevention of neurological complications through early diagnosis and treatment. When early cataracts in childhood, tendon xanthomas, and unexplained neurological symptoms occur together, active suspicion of CTX by the clinician and plasma cholestanol testing are most important.